Sara Nofal

Sara Nofal

Auto-generated profile, based on publicly available information

Sara Nofal

Department of Health Services Research The University of Texas MD Anderson Cancer Center Houston Texas USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Cancer Medicine
Verified
Journal Article
Open access
SNSara Nofal
Sara Nofal
JNJiangong Niu
Jiangong Niu
PRPaul Resong
Paul Resong
JJJeff Jin
Jeff Jin
KMKelly W. Merriman
Kelly W. Merriman
ITIakovos Toumazis
Iakovos Toumazis
Background: Personal history of cancer is an independent risk factor for lung cancer but is omitted from existing lung cancer screening eligibility criteria. In this study, we assess the lung cancer risk among cancer survivors and discuss potential implications for screening.Methods: This was a retrospective, secondary analysis of data from the Surveillance, Epidemiology and End Results (SEER) registry and the MD Anderson Cancer Center (MDACC). We estimated the standardized incidence ratios (SIRs) for lung cancer by site of first primary cancer using data from SEER. We assessed the lung cancer risk among head and neck cancer survivors from MDACC using cumulative incidence and compared the risk ratios (RR) by individuals' screening eligibility status.Results: Other than first primary lung cancer (SIR: 5.10, 95% CI: 5.01–5.18), cancer survivors in SEER with personal history of head and neck cancer (SIR: 3.71, 95% CI: 3.63–3.80) had the highest risk of developing second primary lung cancer, followed by bladder (SIR: 1.86, 95% CI: 1.81–1.90) and esophageal cancers (SIR: 1.78, 95% CI: 1.61–1.96). Head and neck cancer survivors had higher risk to develop lung cancer compared to the National Lung Screening Trial's subjects, (781 vs. 572 per 100,000 person‐years, respectively). Head and neck cancer survivors ineligible for lung cancer screening seen at MDACC had significantly higher lung cancer risk than head and neck cancer survivors from SEER (RR: 1.9, p < 0.001).Conclusion: Personal history of cancer, primarily head and neck cancer, is an independent risk factor for lung cancer and may be considered as an eligibility criterion in future lung cancer screening recommendations.

18 April 2025 in International Journal of Cancer
Verified
Journal Article
Open access
SNSara Nofal
Sara Nofal
EOEdwin Ostrin
Edwin Ostrin
JZJianjun Zhang
Jianjun Zhang
JWJia Wu
Jia Wu
PSPaul Scheet
Paul Scheet
ITIakovos Toumazis
Iakovos Toumazis
Personal history of cancer is an independent risk factor for developing lung cancer. However, it is not considered in the current US lung cancer screening (LCS) guidelines. In this study, we assessed the risk of developing lung cancer among cancer survivors across 24 different sites of first primary cancer stratified by their LCS eligibility status. Using data from the Patient History Database at the University of Texas MD Anderson Cancer Center, we calculated and compared the cumulative incidence of second primary lung cancer, the overall and the LCS eligibility status‐specific, stratified by the site of first primary cancer among cancer survivors. We found that among lung, head and neck (H&N), bladder, cervical, breast, and prostate cancer survivors, the risks of second primary lung cancer were statistically significantly higher compared to the overall risk among all cancer survivors (i.e., all cancer sites combined). Risk ratios (RR) ranged between 1.14 (95%CI:1.00–1.28, p = 0.0431) among prostate cancer survivors to 2.9 (95%CI:2.58–3.26, p < 0.001) among H&N cancer survivors. Other than first primary lung cancer (RR: 1.33; 95%CI:1.14–1.57; p < 0.001), H&N (RR: 1.73; 95%CI:1.45–2.05; p < 0.001) and bladder (RR: 1.32; 95%CI:1–1.74; p = 0.0483) cancer survivors, who were non‐eligible for LCS, had significantly higher lung cancer risk than all cancer survivors. In conclusion, H&N, bladder, cervical, breast, and prostate cancer survivors have a high risk of developing second primary lung cancer. Specifically, personal history of H&N and bladder cancer, even among non‐eligible for LCS individuals, remain at a sufficiently high risk, which warrants further consideration as an independent eligibility factor for LCS guidelines.

28 March 2025 in Lung Cancer
Verified
Journal Article
Open access
RNRenu Sara Nargund
Renu Sara Nargund
SISayaka Ishizawa
Sayaka Ishizawa
MEMaryam Eghbalizarch
Maryam Eghbalizarch
PYPaul Yeh
Paul Yeh
SSSeyyed Mostafa Mousavi Janbeh Saray
Seyyed Mostafa Mousavi Janbeh Saray
ITIakovos Toumazis
Iakovos Toumazis
Natural history models (NHMs) of lung cancer (LC) simulate the disease's natural progression providing a baseline for assessing the impact of interventions. NHMs have been increasingly used to inform public health policies, highlighting their utility. The objective of this scoping review was to summarize existing LC NHMs, identify their limitations, and propose a framework for future NHM development. We searched MEDLINE, Embase, Web of Science, and IEEE Xplore from their inception to October 5, 2023, for peer-reviewed, full-length articles with an LC NHM. Model characteristics, their applications, data sources used, and limitations were extracted and narratively synthesized. From 238 publications, 69 publications were included in our review, corresponding to 22 original LC NHMs and 47 model applications. The majority of the models (n = 15, 68 %) used a microsimulation approach. NHM parameters were predominately informed by cancer registries, trial and institutional data, and literature. Model quality and performance were evaluated in 8 (36 %) models. Twenty (91 %) models included at least one carcinogenesis risk factor-primarily age, sex, and smoking history. Three (14 %) LC NHMs modeled progression in never-smokers; one (5 %) addressed recurrence. Non-tobacco smoking, nodule type, and biomarker expression were not considered in existing NHMs. Based on our findings, we proposed a framework for future LC NHM development which incorporates recurrence, nodule type differentiation, biomarker expression levels, biological factors, and non-smoking-related risk factors. Regular updating and future research are warranted to address limitations in existing NHMs thereby ensuring relevance and accuracy of modeling approaches in the evolving LC landscape.

1 January 2025 in Dermatologic Therapy
Verified
Journal Article
Open access
HNHagar Nofal
Hagar Nofal
AAAmin Amer
Amin Amer
NANourhan Anis
Nourhan Anis
RNRofida Nofal
Rofida Nofal
SNSara Nofal
Sara Nofal
DHDina Hamed
Dina Hamed
Methotrexate is a well‐known chemotherapeutic agent, widely used alone or in combination with other drugs in the treatment of cancer. Methotrexate applications in dermatology have significantly expanded over the years. Methotrexate is an established treatment modality for psoriasis; other indications include vitiligo, atopic dermatitis, immunobullous disorders, alopecia areata, neutrophilic dermatoses, and cutaneous T‐cell lymphoma. To increase the efficacy and reduce the potential adverse effects, different methotrexate forms and modes of delivery have been investigated including intralesional and topical modalities. Herein, dermatologists are introduced to methotrexate different indications in clinical practice, its mechanism of action, and the in‐depth knowledge needed to effectively and safely prescribe methotrexate to their patients with confidence. Mastery of prescribing methotrexate is an essential skill for dermatologists.

27 October 2021 in Journal of Surgical Research
Verified
Journal Article
Open access
SNSara Nofal
Sara Nofal
YYYi-Qian Nancy You
Yi-Qian Nancy You
GCGeorge J. Chang
George J. Chang
EGElizabeth G. Grubbs
Elizabeth G. Grubbs
BBBrian Bednarski
Brian Bednarski
High-resolution pelvic magnetic resonance imaging (MRI) is a critical tool in the management of patients with rectal cancer. An on-line curriculum was developed for surgical trainees on the interpretation of pelvic MRI in rectal cancer for clinical staging and surgical planning. The online curriculum was developed using the six-step approach to curriculum development for medical education. The curriculum incorporated case-based learning, annotated videos, and narrated presentations on key aspects of pelvic MRI in rectal cancer. A pilot study was conducted to assess curriculum effectiveness among Complex General Surgical Oncology (CGSO) fellows using pre- and post-intervention assessments. Of 15 eligible fellows, nine completed the pilot study (60%). The fellows’ median confidence score after completing the online curriculum (40, IQR: 33–46) was significantly higher than their baseline median confidence score (23, IQR: 14–30), p=0.0039. The total practical assessment score significantly increased from a pre-median score of 9 (IQR: 8–11) to a post-median score of 14 (IQR: 13–14), p=0.0078. A subgroup analysis revealed a significant change in the knowledge assessment with a median score of 7 compared to a baseline median score of 4, Z=2.64, p=0.0078. However, the skills assessment showed no significant change. The case-based online curriculum had a positive impact on CGSO fellows’ knowledge and confidence in the utilization of pelvic MRI for patients with rectal cancer. This unique on-line curriculum demonstrates a mechanism to enhance shared educational collaboration across CGSO fellowships and other surgical training programs.

1 February 2020 in The American Journal of Surgery
Verified
Journal Article
Closed access
SNSara Nofal
Sara Nofal
YYY. Nancy You
Y. Nancy You
GCGeorge J. Chang
George J. Chang
EGElizabeth E. Grubbs
Elizabeth E. Grubbs
BBBrian K. Bednarski
Brian K. Bednarski